Amicus Therapeutics
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 2002-01-01
- Employees
- 517
- Market Cap
- $3.3B
- Website
- http://www.amicusrx.com
- Introduction
Amicus Therapeutics, Inc. operates as a biotechnology company. The firm focuses on discovering, developing and delivering medicines for people living with metabolic diseases. Its product portfolio includes first and only approved oral precision medicine for people living with Fabry disease who have amenable genetic variants, a novel, clinical-stage, treatment paradigm for Pompe disease and a rare disease gene therapy portfolio. The company was founded by John Francis Crowley on February 4, 2002 and is headquartered in Princeton, NJ.
A 12-Week Safety and Pharmacodynamic Study of AT1001 (Migalastat Hydrochloride) in Female Participants With Fabry Disease
- First Posted Date
- 2006-03-20
- Last Posted Date
- 2018-10-03
- Lead Sponsor
- Amicus Therapeutics
- Target Recruit Count
- 9
- Registration Number
- NCT00304512
A 24-Week Safety and Pharmacodynamic Study of AT1001 (Migalastat Hydrochloride) in Participants With Fabry Disease
- First Posted Date
- 2006-01-31
- Last Posted Date
- 2018-09-07
- Lead Sponsor
- Amicus Therapeutics
- Target Recruit Count
- 5
- Registration Number
- NCT00283933
A 12-Week Safety and Pharmacodynamic Study of AT1001 (Migalastat Hydrochloride) in Participants With Fabry Disease
- First Posted Date
- 2006-01-31
- Last Posted Date
- 2018-10-31
- Lead Sponsor
- Amicus Therapeutics
- Target Recruit Count
- 4
- Registration Number
- NCT00283959
A Study of AT1001 (Migalastat Hydrochloride) in Participants With Fabry Disease
- First Posted Date
- 2005-09-22
- Last Posted Date
- 2018-10-30
- Lead Sponsor
- Amicus Therapeutics
- Target Recruit Count
- 9
- Registration Number
- NCT00214500
© Copyright 2024. All Rights Reserved by MedPath